Multicenter, Open-label, Two-arm, Parallel-design, Repeat-dose Clinical Trial to Evaluate the PK, Safety, and Tolerability of Four Intramuscular Injections of Risperidone ISM® 75 mg, at 28 Day Intervals in Patients With Schizophrenia

Trial Profile

Multicenter, Open-label, Two-arm, Parallel-design, Repeat-dose Clinical Trial to Evaluate the PK, Safety, and Tolerability of Four Intramuscular Injections of Risperidone ISM® 75 mg, at 28 Day Intervals in Patients With Schizophrenia

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Acronyms PRISMA-2
  • Sponsors Rovi
  • Most Recent Events

    • 28 Jul 2016 Results from this trial were presented at the 24th European Congress of Psychiatry, according to a Rovi media release.
    • 04 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 04 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top